News

Rapiacta, an intravenous injection for treatment of influenza infection, was launched for adult use in Japan on January 27, 2010. Shionogi filed a NDA for adult use of

Michael Fort, chief executive of Synexus, said: “Once again our model has been shown to deliver the right numbers of patients at the right time even when it

Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and is said to present a potentially new approach for the treatment of certain autoimmune diseases.

John Weinstein, principal investigator of the project, said: “L-ASP is a standard component of leukemia chemotherapy regimens, but it’s not used yet against solid tumors due to erratic

The company said that the certification represents a step toward achieving one of the company’s major goals for its labelstock and RFID facilities worldwide: developing Environmental Management Systems

Under the agreement, Dstl has assigned all patent rights and know-how associated with the antimicrobial peptides for commercial use to Isogenica. Isogenica will exclusively market and distribute the

Leslie Hudson, president and CEO of AVI BioPharma, said: “AVI shares a commitment with the Foundation to Eradicate Duchenne and CureDuchenne to advance the research and development of

Reportedly, through this alliance, BASF is expected to add spray drying of APIs and formulations to its offerings as a provider of custom synthesis services for small molecules

iGCP trials conform to a set of internationally recognised ethical and scientific quality requirements, providing assurance that data is credible and accurate. Ensuring e-Therapeutics’ clinical trials comply with